Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
RESEARCH TOOLSreports
Holding LXEO?
Track your performance easily
LXEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.67 - $19.50
Previous CloseN/A
Volume22.32K
Average Volume (3M)247.08K
Market Cap
$184.51M
Enterprise Value$152.27M
Total Cash (Recent Filing)$77.33M
Total Debt (Recent Filing)$10.65M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Mar 17, 2025EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.84
Shares Outstanding33,065,950
10 Day Avg. Volume296,630
30 Day Avg. Volume247,076
Standard Deviation0.18
R-Squared0.26
Alpha-0.10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.07
Forecast
1Y Price Target
$23.80Price Target Upside356.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Lexeo Therapeutics, Inc. News
PremiumCompany Announcements
Lexeo Therapeutics Appoints Dr. Kyle Rasbach as CFO
PremiumCompany Announcements
Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report
Bulls Say, Bears Say
Bulls Say
Clinical Data And Approval PotentialData from Cohort 3 could potentially exceed FDA's requirements for approval, enhancing the regulatory chances for Lexeo.
Financial StabilityLexeo ended Q1 with $195.1 mm in cash, cash equivalents and marketable securities, reflecting a strong financial position.
Regulatory PathwayThe alignment with FDA on the registrational targets of LVMI reductions and FXN expression seems achievable, indicating a positive regulatory pathway.
Bears Say
Clinical UncertaintyThe APOE 2:4 ratio achieved in patients was markedly lower than typically observed in true heterozygotes, raising uncertainty about clinical benefit.
Financial PerformanceThird-quarter financials did not meet consensus estimates, reporting a higher loss than expected.
Study ResultsThe study did not show signs that the magnitude of effects can drive cognitive benefit in treated patients, and a larger study would be required to evaluate cognitive benefits.
---
Ownership Overview
1.51% Insiders
10.86% Mutual Funds
53.39% Other Institutional Investors
27.57% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LXEO FAQ
What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?
Lexeo Therapeutics, Inc. lowest stock price was $4.67 and its highest was $19.50 in the past 12 months.
What is Lexeo Therapeutics, Inc.’s market cap?
Lexeo Therapeutics, Inc.’s market cap is $184.51M.
When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?
Lexeo Therapeutics, Inc.’s upcoming earnings report date is Mar 17, 2025 which is in 44 days.
How were Lexeo Therapeutics, Inc.’s earnings last quarter?
Lexeo Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.678 by -$0.212.
Is Lexeo Therapeutics, Inc. overvalued?
According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued.
Does Lexeo Therapeutics, Inc. pay dividends?
Lexeo Therapeutics, Inc. does not currently pay dividends.
What is Lexeo Therapeutics, Inc.’s EPS estimate?
Lexeo Therapeutics, Inc.’s EPS estimate is -0.81.
How many shares outstanding does Lexeo Therapeutics, Inc. have?
Lexeo Therapeutics, Inc. has 33,065,950 shares outstanding.
What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?
Lexeo Therapeutics, Inc. reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.678. Following the earnings report the stock price went down -0.65%.
Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LXEO
---
Lexeo Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.80 (356.81% Upside)
$23.80 (356.81% Upside)
Blogger Sentiment
Bullish
LXEO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 394.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $104.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.28%
12-Months-Change
Fundamentals
Return on Equity
-107.21%
Trailing 12-Months
Asset Growth
217.71%
Trailing 12-Months
Company Description
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
---
LXEO Stock 12 Month Forecast
Average Price Target
$23.80
▲(356.81% Upside)
Technical Analysis
Bluebird Bio
―
Ultragenyx Pharmaceutical
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering LXEO
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-41.61%
reiterated a buy rating 11 days ago
Copying Luca Issi's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -41.61% per trade.
---